CEU 2026: Shared Decision-Making in Growth Hormone Deficiency: Personalizing Treatment in the Era of Long-Acting Therapies

Availability

On-Demand

Release on Oct 23, 2026 10:00 AM Central Daylight Time
Expires on Dec 31, 2026

Cost

$0.00

Credit Offered

1 AMA PRA Category 1 Credit

1 ABIM-MOC Point

1 Participation Credit

Course Description
Target Audience
Learning Objectives
Accreditation Statement
Disclosure Statement
Faculty and Disclosures

This session will provide practical guidance on the clinical use of long-acting growth hormone (LAGH) therapies for the treatment of pediatric and adult growth hormone disease (GHD).

This program is supported by educational grants from Novo Nordisk, Pfizer, and Ascendis Pharma.

The intended audience for this Clinical Endocrinology Update (CEU) 2026 live virtual Ancillary Symposium is endocrinologists, physician associates, nurse practitioners, and allied healthcare professionals who treat patients with growth hormone deficiencies.

Discuss the benefits of growth hormone replacement therapy in both children and adults with GHD
Implement shared-decision making to choose between daily and long-acting GH therapies for children and adults with GHD
Differentiate between LAGH therapies approved for pediatric and/or adult GHD in terms of efficacy, safety, administration, dosing and monitoring requirements
Apply best practice to initiate LAGH therapies in appropriate adults and children with GHD, and monitor IGF-1 levels to inform dose adjustments

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Maintenance of Certification (MOC)
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 1.00 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For questions about content or obtaining CME credit, please contact the Endocrine Society at info@endocrine.org

Statement of Independence
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

Disclosure Policy
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 24 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

Maria Fleseriu, MD
Professor, Pituitary Center, Endocrinology and Neurosurgical Surgery
Oregon Health & Science University

Aristides Maniatis, MD
Pediatric Endocrinologist
Rocky Mountain Pediatric Endocrinology, PC

STATEMENT OF INDEPENDENCE

As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s peer reviewers.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Maria Fleseriu, MD: NovoNordisk (Consultant); Pfizer (Consultant).

Aristides K. Maniatis, MD: NovoNordisk (Advisory Board, Clinical Trial Investigator, Honorarium Recipient, Speakers' Bureau); Ascendis Pharma (Advisory Board, Clinical Trial Investigator, Honorarium Recipient, Speakers' Bureau); OPKO Health (Clinical Trial Investigator); Pfizer (Advisory Board, Clinical Trial Investigator, Honorarium Recipient, Speakers' Bureau).

The Endocrine Society staff involved in the development of this CME activity reported no relevant financial relationships.

The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This educational activity is supported by an educational grants from Ascendis Pharma, Novo Nordisk Inc, and Pfizer.


EndoCareers \| Contact Us \| Privacy Policy \| Terms of Use	CONNECT WITH US
© 2021 Copyright Endocrine Society. All rights reserved.	2055 L Street NW, Suite 600 \| Washington, DC 20036 202.971.3636 \| 888.363.6274